QQ客服 官方微博 反馈留言

	The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
	Wang Juan; Ma Shumei; Chen Xiuhua; Zhang Sanqi; Wang Zhiyong; Mei Qibing
刊名	Investigational new drugs
	2018
关键词	Sorafenib Angiogenesis Lung cancer S1 Phosphorylation
ISSN号	1573-0646
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2906830
专题	西安交通大学
推荐引用方式 GB/T 7714	Wang Juan,Ma Shumei,Chen Xiuhua,et al. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.[J]. Investigational new drugs,2018.
APA	Wang Juan,Ma Shumei,Chen Xiuhua,Zhang Sanqi,Wang Zhiyong,&Mei Qibing.(2018).The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling..Investigational new drugs.
MLA	Wang Juan,et al."The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.".Investigational new drugs (2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。